Howie Bartz is a summa cum laude graduate of Daemen College. In 2007, he founded Meditech, LLC, a provider of durable medical equipment and ancillary services. Through this company, Howie Bartz offers pharmacogenetic testing.
More than 2.2 billion cases of adverse drug events (ADE) occur every year, with as many as 100,000 events resulting in death. Pharmacogenetic testing is helpful in identifying potential ADEs and detecting individuals who are one of the 20 percent to 30 percent of pain patients who suffer from a genetic opioid metabolic defect (GOMD). Pharmacogenetic testing also helps increase drug efficacy. Presently, less than 60 percent of patients taking prescription pain medication enjoy a mitigation of symptoms. In these situations, an increased dosage can lead to an overdose. In fact, prescription opioid overdoses account for more deaths than cocaine and heroin combined as of 2014. Finally, pharmacogenetic testing can improve patient compliance because patients who receive genetic test results are more compliant with prescription guidelines.